Seeking Alpha

AstraZeneca (AZN) intends to axe 2,300 sales and administration positions as part of its...

AstraZeneca (AZN) intends to axe 2,300 sales and administration positions as part of its overhaul, adding to 1,600 R&D job cuts already announced. AstraZeneca, which is due to lay out its strategy at an investor meeting today, plans to continue paying dividends and to buy in new technology The company is paying up to $420M plus royalties for the rights to the technology of Moderna, a developer of drugs using messenger RNA, which is involved in protein production in cells. (PR I, II)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|